Heat Biologics Inc (NASDAQ:HTBX) – Research analysts at Zacks Investment Research reduced their FY2019 earnings per share (EPS) estimates for Heat Biologics in a report released on Monday, June 3rd, according to Zacks Investment Research. Zacks Investment Research analyst J. Vandermosten now forecasts that the biopharmaceutical company will earn ($0.57) per share for the year, down from their previous estimate of ($0.55). Zacks Investment Research also issued estimates for Heat Biologics’ FY2020 earnings at ($0.61) EPS and FY2021 earnings at ($0.66) EPS.
Several other brokerages also recently issued reports on HTBX. ValuEngine raised shares of Heat Biologics from a “sell” rating to a “hold” rating in a research report on Thursday, May 9th. Alliance Global Partners set a $6.00 price objective on shares of Heat Biologics and gave the stock a “buy” rating in a research report on Friday, May 17th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $7.67.
Heat Biologics (NASDAQ:HTBX) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.17) EPS for the quarter. Heat Biologics had a negative net margin of 319.80% and a negative return on equity of 68.17%. The firm had revenue of $0.70 million during the quarter.
Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in Heat Biologics in the fourth quarter valued at $55,000. CVI Holdings LLC bought a new position in Heat Biologics in the fourth quarter valued at $1,527,000. Vanguard Group Inc. grew its position in Heat Biologics by 20.6% in the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after purchasing an additional 136,256 shares in the last quarter. Finally, Vanguard Group Inc grew its position in Heat Biologics by 20.6% in the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after purchasing an additional 136,256 shares in the last quarter. 5.94% of the stock is owned by institutional investors and hedge funds.
Heat Biologics Company Profile
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Recommended Story: CD Ladder
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.